

Resource Summary Report

Generated by [NIF](#) on Sep 19, 2026

H-EMC-SS

RRID:CVCL_1238

Type: Cell Line

Proper Citation

RCB Cat# RCB0508, RRID:CVCL_1238

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1238

Proper Citation: RCB Cat# RCB0508, RRID:CVCL_1238

Description: Cell line H-EMC-SS is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Extraskelatal myxoid chondrosarcoma

Defining Citation: [PMID:20164919](#), [PMID:20215515](#), [PMID:27397505](#), [PMID:30894373](#), [PMID:34413129](#), [PMID:35839778](#)

Comments: Caution: Does not harbor a gene fusion involving EWSR1 which is a hallmark of extraskelatal myxoid chondrosarcoma (PubMed=34413129)., Population: Japanese., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: H-EMC-SS

Synonyms: HEMCSS, HEMC-SS

Cross References: CLO:CLO_0003701, CLO:CLO_0051381, CLDB:cl1625, CLDB:cl4965, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-3610, BioSample:SAMD00005690, BioSample:SAMN03472276, cancercellines:CVCL_1238, Cell_Model_Passport:SIDM00535, ChEMBL-Cells:ChEMBL3308736, ChEMBL-Targets:ChEMBL1075451, Cosmic:907290, Cosmic-CLP:907290, DepMap:ACH-001519, ECACC:94042258, EGA:EGAS00001000978, FANTOM5_SSTAR:10410-106B5, GDSC:907290, GEO:GSM827448, GEO:GSM1669877, IARC_TP53:21353,

ICLC:HTL99016, LINCX_LDP:LCL-1458, PharmacDB:HEMCSS_419_2019, PRIDE:PXD030304, Progenetix:CVCL_1238, PubChem_Cell_line:CVCL_1238, RCB:RCB0508, Wikidata:Q54871889

ID: CVCL_1238

Vendor: RCB

Catalog Number: RCB0508

Record Creation Time: 20220427T220221+0000

Record Last Update: 20260913T003757+0000

Ratings and Alerts

No rating or validation information has been found for H-EMC-SS.

No alerts have been found for H-EMC-SS.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 3 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Nelson BE, et al. (2025) Phase Ib Study of Pembrolizumab in Combination with Intratumoral Injection of Clostridium novyi-NT in Patients with Advanced Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research, 31(18), 3864.

Subbiah V, et al. (2023) Preclinical Characterization and Phase I Trial Results of INBRX-109, A Third-Generation, Recombinant, Humanized, Death Receptor 5 Agonist Antibody, in Chondrosarcoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 29(16), 2988.

Gartrell J, et al. (2021) SLFN11 is Widely Expressed in Pediatric Sarcoma and Induces Variable Sensitization to Replicative Stress Caused By DNA-Damaging Agents. Molecular cancer therapeutics, 20(11), 2151.